CurrentUnitedHealthcarePolicy CS371ID.A

Injectable Dermal Fillers and Bulking Agents (for Idaho Only)

State-specific UnitedHealthcare medical policy (Idaho only, including Idaho Medicaid Plus) governing coverage of injectable dermal fillers and injectable bulking agents for facial lipoatrophy in people with HIV and for vocal fold insufficiency, including procedure/HCPCS codes and clinical context.

Policy Summary

PayerUnitedHealthcare

PolicyInjectable Dermal Fillers and Bulking Agents (for Idaho Only)

Policy CodePolicy CS371ID.A

Change TypeNew Medical Policy

Effective DateJun 1, 2025

Next Review Date

Key ActionMedical records documentation may be required to demonstrate the indication (e.g., HIV-associated facial lipoatrophy or vocal fold insufficiency) and adherence to FDA labeled indications for bulking agents.

SourceLink

POLICY UPDATE CHANGES

New Medical Policy effective 06/01/2025.

2Specific products covered for HIV facial lipoatrophy (Radiesse, Sculptra)

All othersOther dermal fillers

FDA labeledBulking agents coverage condition

Coverage Summary

This Idaho-specific UnitedHealthcare medical policy (Policy Number CS371ID.A) governs coverage of injectable dermal fillers and injectable bulking agents for HIV-associated facial lipoatrophy and vocal fold insufficiency. Effective date: June 1, 2025. The policy scope applies only to the state of Idaho, including Idaho Medicaid Plus. Coverage stance is mixed: specific products and indications are considered medically necessary while other uses are not. The policy’s headline coverage statements specify that Radiesse and Sculptra are reconstructive and medically necessary for facial defects from HIV-associated facial lipoatrophy but are cosmetic and not medically necessary for other indications; additionally, injectable bulking agents are medically necessary for vocal fold insufficiency when used according to FDA labeling (indications, contraindications, warnings, precautions).

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Medical-Necessity Criteria

Dermal Filler Injections

Coverage statements:

ANY of the following

Radiesse and Sculptra are considered reconstructive and medically necessary for the treatment of facial defects due to facial lipoatrophy in individuals living with human immunodeficiency virus (HIV) infection.
Radiesse and Sculptra are considered cosmetic and not medically necessary for all other indications.
The use of all other dermal filler products is considered cosmetic and not medically necessary.

Injectable Bulking Agents

Coverage when used according to FDA labeling:

Injectable bulking agents are proven and medically necessary for the treatment of vocal fold insufficiency/ dysfunction when used according to U.S. Food and Drug Administration (FDA) labeled indications, contraindications, warnings, and precautions.

Adhere to FDA labeled indications, contraindications, warnings, and precautions.

Provider Actions & Billing Guidance

Documentation Required

Medical record documentation may be required

Medical records documentation may be required to assess whether the member meets clinical criteria for coverage and to demonstrate the indication (e.g., HIV-associated facial lipoatrophy or vocal fold insufficiency) and adherence to FDA labeled indications for bulking agents.

Examples of indications: HIV-associated facial lipoatrophy
Vocal fold insufficiency

Billing Rule

Code usage guidance

Listed HCPCS codes (G0429, L8607, Q2026, Q2028) are provided for reference and their inclusion does not guarantee coverage or reimbursement; check federal, state, or contractual requirements.

G0429
L8607
Q2026
Q2028
Inclusion of a code does not imply right to reimbursement or guarantee claim payment; verify federal, state, and contractual requirements

Background & Evidence

Clinical rationale: Injectable fillers have been FDA-approved to treat facial lipoatrophy in people with HIV; specifically, Sculptra (poly-L-lactic acid) and Radiesse (calcium hydroxylapatite) are identified as approved options to restore or correct facial fat loss in this population. Clinical trials and reviews cited in the policy report objective and patient-reported improvements in appearance and quality of life (for example, Vallejo et al. reported objective improvement in 53% of cases and overall patient satisfaction), and Jagdeo et al. assigned a B-level recommendation for PLLA (Sculptra) and a C-level recommendation for CaHA (Radiesse) for HIV facial lipoatrophy.

For vocal fold insufficiency, bulking agents (including CaHA) are used to improve glottal closure and voice outcomes by medializing the affected vocal fold(s). Studies cited demonstrate improved voice measures and clinically meaningful benefit durations (for example, CaHA showed average benefit durations around 18.6 months with significant improvements on Voice Handicap Index and other voice outcome measures at 12 months).

Guideline context: the policy references relevant specialty guidance supporting use of injection augmentation for glottal insufficiency — including the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) guidance describing vocal fold injection medialization as a therapeutic option and a temporary intervention to reduce need for later reconstruction, the American Laryngological Association (ALA) 2019 guideline that lists indications and contraindications for vocal fold injection augmentation, and the UK NICE guidance noting efficacy of collagen injection for short-term symptom relief. The policy also notes FDA approvals and clearances for the listed fillers and for bulking agents used for vocal cord medialization.

Study	Key results / duration
Vallejo et al. (2018)
Clinical trial (n=147) of HIV-associated facial lipoatrophy treated with Sculptra, Radiesse, Aquamid, or autologous fat: objective improvement in 53% of cases; patient-reported satisfaction and quality-of-life improvement; 24-month follow-up
Jagdeo et al. (2015)
Systematic review: PLLA (Sculptra) assigned B-level recommendation; CaHA (Radiesse) assigned C-level recommendation; literature supports effectiveness and general safety for HIV facial lipoatrophy
Carroll & Rosen (2011); Rosen et al. (2009)
CaHA (Radiesse) for vocal fold augmentation: improved voice measures up to 12 months (Rosen et al. 2009); average duration of benefit ~18.6 months (range 8–36 months) with long-term effectiveness (Carroll & Rosen 2011)

Definitions

Facial lipoatrophyLoss of facial fat often associated with HIV and antiretroviral therapy, resulting in facial defects addressed by reconstructive fillers.

Vocal fold insufficiencyCondition in which one or both vocal cords do not close correctly, causing vocal fatigue, poor voice quality, and increased aspiration risk.